Alloy speeds up timeline for complex fibrosis targets, completing successful antibody discovery collab with Mediar.
Alloy Therapeutics Inc., a biotechnology company based in Boston, has recently completed a successful antibody discovery collaboration with Mediar Therapeutics. Through the utilization of Alloy's ATX-Gx™ human transgenic mouse platform, as well as advanced genetic immunization techniques and AI/ML-enabled discovery workflows, Alloy was able to provide a set of unique binders targeting a challenging new target. This collaboration has marked a significant milestone for Alloy, showcasing its commitment to expanding access to cutting-edge drug discovery technologies.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments